Let’s talk about America’s favorite antibiotic: the Z-Pak. Five little pills, once a day, and you’re done in five days. It’s the fast food of medicine — convenient, addictive, and nutritionally useless for what you actually ordered it for.
Here’s how this goes, roughly forty times a year in my practice. A parent calls, sometimes irritated, sometimes just tired: “My telehealth visit said my kid had a sinus infection and gave us a Z-Pak. It’s been two days and nothing’s changed.” I pull up the chart. Symptoms for 48 hours. No fever above 101. No facial pain, no “double sickening” where things got better then suddenly worse. In other words: a garden-variety viral upper respiratory infection that was never a sinus infection to begin with, treated with an antibiotic that wouldn’t have covered it anyway.
This isn’t a coincidence. It’s a pattern, and the pattern has a name: azithromycin is easy to prescribe, easy to take, and easy to be wrong about.
Why everyone loves it (and why that’s the problem)
Azithromycin’s whole marketing pitch is convenience. One pill a day for five days, versus amoxicillin’s twice-a-day, taste-like-bubblegum-gone-wrong, ten-day slog. For a rushed telehealth visit — where the “exam” is a kid holding a phone at a weird angle while you ask if it hurts to swallow — the Z-Pak is the path of least resistance. Pun intended, because resistance is exactly the problem.
Streptococcus pneumoniae, the bacteria most commonly behind kids’ ear infections, sinus infections, and pneumonia, now shows macrolide (azithromycin’s drug class) resistance rates in the 40-55% range nationally, and higher than that in respiratory-source isolates specifically (Gupta et al., Open Forum Infectious Diseases). For context, the Infectious Diseases Society of America says you should abandon a macrolide as empiric therapy once resistance crosses 25% (Contagion Live). We blew past that threshold over a decade ago and just… kept prescribing it. Convenience won. Microbiology lost.
What the actual guidelines say
The American Academy of Pediatrics doesn’t equivocate on this one: amoxicillin (high-dose, please) is first-line for acute otitis media and acute bacterial sinusitis in kids. Azithromycin isn’t even a solid second-line option — it’s reserved for children with a documented, severe (anaphylactic-type) penicillin allergy, and even then it’s a compromise, not a win (UCSF Infectious Diseases Management Program; Arkansas Children’s Pediatric Guideline). Part of the reason isn’t just resistance — azithromycin also doesn’t reach great concentrations in middle ear fluid or the sinuses, so even when it does work, it’s often working with one hand tied behind its back.
So when a five-day course of a drug with a coin-flip’s chance of killing the bacteria in question gets prescribed for a two-day-old viral illness that was never bacterial in the first place, nobody should be surprised when day three rolls around and the kid still has a runny nose and a resigned parent on the phone with me.
The real fix isn’t a different pill
To be clear, this isn’t really an anti-Zithromax rant so much as an anti-“diagnosing a sinus infection over video chat on day two of a cold” rant. Most of these calls aren’t azithromycin failing at its job. They’re azithromycin being asked to do a job that didn’t need doing, because true acute bacterial sinusitis in kids typically requires ten-plus days of symptoms, or a clear worsening after initial improvement — not 48 hours of congestion and a tired parent with a co-pay to justify.
If your kid does need an antibiotic, it should almost always be amoxicillin — cheaper, better studied, better tolerated, and still doing its job against the bugs that actually cause these infections. The Z-Pak isn’t a bad drug. It’s just a wildly overused one, propped up by how easy it is to hand out on a five-minute video call instead of the slower, less lucrative work of asking “how many days has this actually been going on?”
Any advice or information given in this blog should not supersede consultation with your pediatrician or practitioner of choice. Every child is unique, and medical decisions must be made in partnership with the healthcare provider who knows your child’s full history. This blog is intended for educational and informational purposes only, not as a substitute for personalized medical care.
If you are looking for medical advice that is evidence-based, ethically grounded, and uncompromised by industry influence, you are in the right place.
Sources
Gupta V, et al. “A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant Streptococcus pneumoniae.” Open Forum Infectious Diseases.
UCSF Infectious Diseases Management Program. “Acute Otitis Media” clinical guidance.
Arkansas Children’s Hospital. “Acute Otitis Media / Acute Bacterial Sinusitis Pediatric Guideline.”